Mahmoud Ma Elsayed1, Mahmoud E Mostafa2, Eman Alaaeldin2,3, Hatem Aa Sarhan2, Montaser ShA Shaykoon4, Shady Allam5, Ahmed Rh Ahmed6, Bakheet Em Elsadek7. 1. Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag, Egypt. 2. Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt. 3. Department of Clinical Pharmacy, Deraya University, Minia, Egypt. 4. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt. 5. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. 6. Department of Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt. 7. Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt.
Abstract
PURPOSE: Over the past 30 years, no consistent survival benefits have been recorded for anticancer agents of advanced hepatocellular carcinoma (HCC), except for the multikinase inhibitor sorafenib (Nexavar®), which clinically achieves only ~3 months overall survival benefit. This modest benefit is attributed to limited aqueous solubility, slow dissolution rate and, consequently, limited absorption from the gastrointestinal tract. Thus, novel formulation modalities are in demand to improve the bioavailability of the drug to attack HCC in a more efficient manner. In the current study, we aimed to design a novel sorafenib-loaded carbon nanotubes (CNTs) formula that is able to improve the therapeutic efficacy of carried cargo against HCC and subsequently investigate the antitumour activity of this formula. MATERIALS AND METHODS: Sorafenib was loaded on functionalized CNTs through physical adsorption, and an alginate-based method was subsequently applied to microcapsulate the drug-loaded CNTs (CNTs-SFN). The therapeutic efficacy of the new formula was estimated and compared to that of conventional sorafenib, both in vitro (against HepG2 cells) and in vivo (in a DENA-induced HCC rat model). RESULTS: The in vitro MTT anti-proliferative assay revealed that the drug-loaded CNTs formula was at least two-fold more cytotoxic towards HepG2 cells than was sorafenib itself. Moreover, the in vivo animal experiments proved that our innovative formula was superior to conventional sorafenib at all assessed end points. Circulating AFP-L3% was significantly decreased in the CNTs-SFN-MCs-treated group (14.0%) in comparison to that of the DENA (40.3%) and sorafenib (38.8%) groups. This superiority was further confirmed by Western blot analysis and immunofluorescence assessment of some HCC-relevant biomarkers. CONCLUSION: Our results firmly suggest the distinctive cancer-suppressive nature of CNTs-SFN-MCs, both against HepG2 cells in vitro and in a DENA-induced HCC rat model in vivo, with a preferential superiority over conventional sorafenib.
PURPOSE: Over the past 30 years, no consistent survival benefits have been recorded for anticancer agents of advanced hepatocellular carcinoma (HCC), except for the multikinase inhibitor sorafenib (Nexavar®), which clinically achieves only ~3 months overall survival benefit. This modest benefit is attributed to limited aqueous solubility, slow dissolution rate and, consequently, limited absorption from the gastrointestinal tract. Thus, novel formulation modalities are in demand to improve the bioavailability of the drug to attack HCC in a more efficient manner. In the current study, we aimed to design a novel sorafenib-loaded carbon nanotubes (CNTs) formula that is able to improve the therapeutic efficacy of carried cargo against HCC and subsequently investigate the antitumour activity of this formula. MATERIALS AND METHODS: Sorafenib was loaded on functionalized CNTs through physical adsorption, and an alginate-based method was subsequently applied to microcapsulate the drug-loaded CNTs (CNTs-SFN). The therapeutic efficacy of the new formula was estimated and compared to that of conventional sorafenib, both in vitro (against HepG2 cells) and in vivo (in a DENA-induced HCC rat model). RESULTS: The in vitro MTT anti-proliferative assay revealed that the drug-loaded CNTs formula was at least two-fold more cytotoxic towards HepG2 cells than was sorafenib itself. Moreover, the in vivo animal experiments proved that our innovative formula was superior to conventional sorafenib at all assessed end points. Circulating AFP-L3% was significantly decreased in the CNTs-SFN-MCs-treated group (14.0%) in comparison to that of the DENA (40.3%) and sorafenib (38.8%) groups. This superiority was further confirmed by Western blot analysis and immunofluorescence assessment of some HCC-relevant biomarkers. CONCLUSION: Our results firmly suggest the distinctive cancer-suppressive nature of CNTs-SFN-MCs, both against HepG2 cells in vitro and in a DENA-induced HCC rat model in vivo, with a preferential superiority over conventional sorafenib.
Authors: Zahid Hussain; Shahzeb Khan; Muhammad Imran; Muhammad Sohail; Syed Wadood Ali Shah; Marcel de Matas Journal: Drug Deliv Transl Res Date: 2019-06 Impact factor: 4.617
Authors: Mohammad Hossein Ahmadi Azqhandi; Bahman Vasheghani Farahani; Nasibe Dehghani Journal: Mater Sci Eng C Mater Biol Appl Date: 2017-05-14 Impact factor: 7.328
Authors: Scott M Wilhelm; Lila Adnane; Philippa Newell; Augusto Villanueva; Josep M Llovet; Mark Lynch Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: M Kin; M Sata; T Ueno; T Torimura; S Inuzuka; R Tsuji; K Sujaku; M Sakamoto; H Sugawara; S Tamaki; K Tanikawa Journal: J Hepatol Date: 1997-10 Impact factor: 25.083
Authors: Eman Alaaeldin; Heba A Abou-Taleb; Soad A Mohamad; Mahmoud Elrehany; Shereen S Gaber; Heba F Mansour Journal: Int J Nanomedicine Date: 2021-01-08
Authors: Mohammed S Saddik; Mahmoud M A Elsayed; Mohamed Salaheldin A Abdelkader; Mohamed A El-Mokhtar; Jelan A Abdel-Aleem; Ahmed M Abu-Dief; Mostafa F Al-Hakkani; Hatem S Farghaly; Heba A Abou-Taleb Journal: Pharmaceutics Date: 2021-02-06 Impact factor: 6.321
Authors: Mahmoud M A Elsayed; Moustafa O Aboelez; Bakheet E M Elsadek; Hatem A Sarhan; Khaled Ali Khaled; Amany Belal; Ahmed Khames; Yasser A Hassan; Amany A Abdel-Rheem; Eslam B Elkaeed; Mohamed Raafat; Mahmoud Elkot Mostafa Elsadek Journal: Pharmaceutics Date: 2022-04-18 Impact factor: 6.525
Authors: Mahmoud M A Elsayed; Tarek M Okda; Gamal M K Atwa; Gamal A Omran; Atef E Abd Elbaky; Abd El Hakim Ramadan Journal: Pharmaceutics Date: 2021-05-02 Impact factor: 6.321
Authors: György Babos; Joanna Rydz; Michal Kawalec; Magdalena Klim; Andrea Fodor-Kardos; László Trif; Tivadar Feczkó Journal: Int J Mol Sci Date: 2020-10-03 Impact factor: 5.923
Authors: Mohammed S Saddik; Mahmoud M A Elsayed; Mohamed A El-Mokhtar; Haitham Sedky; Jelan A Abdel-Aleem; Ahmed M Abu-Dief; Mostafa F Al-Hakkani; Hazem L Hussein; Samah A Al-Shelkamy; Fatma Y Meligy; Ali Khames; Heba A Abou-Taleb Journal: Pharmaceutics Date: 2022-01-05 Impact factor: 6.321
Authors: Taghreed S Alnusaire; Ahmed M Sayed; Abeer H Elmaidomy; Mohammad M Al-Sanea; Sarah Albogami; Mha Albqmi; Bassam F Alowaiesh; Ehab M Mostafa; Arafa Musa; Khayrya A Youssif; Hesham Refaat; Eman M Othman; Thomas Dandekar; Eman Alaaeldin; Mohammed M Ghoneim; Usama Ramadan Abdelmohsen Journal: Antioxidants (Basel) Date: 2021-11-23